| Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy EC Morris, SS Neelapu, T Giavridis, M Sadelain Nature Reviews Immunology 22 (2), 85-96, 2022 | 450 | 2022 |
| Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation KS Peggs, A Hunter, R Chopra, A Parker, P Mahendra, D Milligan, ... The Lancet 365 (9475), 1934-1941, 2005 | 347 | 2005 |
| Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma E Morris, K Thomson, C Craddock, P Mahendra, D Milligan, G Cook, ... Blood 104 (13), 3865-3871, 2004 | 321 | 2004 |
| Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses KS Peggs, K Thomson, DP Hart, J Geary, EC Morris, K Yong, ... Blood 103 (4), 1548-1556, 2004 | 276 | 2004 |
| Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene–transduced human T cells SA Xue, L Gao, D Hart, R Gillmore, W Qasim, A Thrasher, J Apperley, ... Blood 106 (9), 3062-3067, 2005 | 245 | 2005 |
| The evolution of cellular deficiency in GATA2 mutation RE Dickinson, P Milne, L Jardine, S Zandi, SI Swierczek, N McGovern, ... Blood, The Journal of the American Society of Hematology 123 (6), 863-874, 2014 | 232 | 2014 |
| Lentiviral gene therapy for X-linked chronic granulomatous disease DB Kohn, C Booth, EM Kang, SY Pai, KL Shaw, G Santilli, M Armant, ... Nature medicine 26 (2), 200-206, 2020 | 220 | 2020 |
| Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient W Qasim, M Brunetto, AJ Gehring, SA Xue, A Schurich, A Khakpoor, ... Journal of hepatology 62 (2), 486-491, 2015 | 216 | 2015 |
| Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious … EC Morris, P Rebello, KJ Thomson, KS Peggs, C Kyriakou, AH Goldstone, ... Blood 102 (1), 404-406, 2003 | 215 | 2003 |
| Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma KJ Thomson, EC Morris, A Bloor, G Cook, D Milligan, A Parker, F Clark, ... Journal of Clinical Oncology 27 (3), 426-432, 2009 | 198 | 2009 |
| Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity C Roddie, JPV Paul, R Benjamin, CI Gallimore, J Xerry, JJ Gray, ... Clinical Infectious Diseases 49 (7), 1061-1068, 2009 | 176 | 2009 |
| T-cell–depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in … KJ Thomson, EC Morris, D Milligan, AN Parker, AE Hunter, G Cook, ... Journal of Clinical Oncology 28 (23), 3695-3700, 2010 | 162 | 2010 |
| CD3 limits the efficacy of TCR gene therapy in vivo M Ahmadi, JW King, SA Xue, C Voisine, A Holler, GP Wright, J Waxman, ... Blood, The Journal of the American Society of Hematology 118 (13), 3528-3537, 2011 | 146 | 2011 |
| A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection EC Morris, A Tsallios, GM Bendle, S Xue, HJ Stauss Proceedings of the National Academy of Sciences 102 (22), 7934-7939, 2005 | 137 | 2005 |
| Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation KJ Thomson, KS Peggs, P Smith, J Cavet, A Hunter, A Parker, ... Bone marrow transplantation 41 (9), 765-770, 2008 | 130 | 2008 |
| Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell–depleted allogeneic transplantation for Hodgkin … KS Peggs, I Kayani, N Edwards, P Kottaridis, AH Goldstone, DC Linch, ... Journal of Clinical Oncology 29 (8), 971-978, 2011 | 129 | 2011 |
| Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen S Thomas, SA Xue, CRM Bangham, BK Jakobsen, EC Morris, HJ Stauss Blood, The Journal of the American Society of Hematology 118 (2), 319-329, 2011 | 127 | 2011 |
| EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity AC Lankester, MH Albert, C Booth, AR Gennery, T Güngör, M Hönig, ... Bone Marrow Transplantation 56 (9), 2052-2062, 2021 | 124 | 2021 |
| Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution R Chakraverty, G Orti, M Roughton, J Shen, A Fielding, P Kottaridis, ... Blood, The Journal of the American Society of Hematology 116 (16), 3080-3088, 2010 | 113 | 2010 |
| Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells S Thomas, SA Xue, M Cesco-Gaspere, E San José, DP Hart, V Wong, ... The Journal of Immunology 179 (9), 5803-5810, 2007 | 111 | 2007 |
